Can we build it better? Using BAC genetics to engineer more effective cytomegalovirus vaccines

Journal of Clinical Investigation

Volumn 120, Issue 12, 2010, Pages 4192-4197

  Schleiss, Mark R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DNA MODIFICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; INNATE IMMUNITY; NATURAL KILLER CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; REINFECTION; VACCINATION;

ANIMALS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; GENES, VIRAL; GENETIC ENGINEERING; HERPESVIRIDAE INFECTIONS; HUMANS; KILLER CELLS, NATURAL; MICE; MUROMEGALOVIRUS; VIRAL VACCINES;

EID: 78649871259     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45250     Document Type: Note

References (25)

1. Bale JF, Miner L, Petheram SJ. Congenital cyto-megalovirus infection. Curr Treat Options Neurol. 2002;4(3):225-230.
2. Cheeran MC, Lokensgard JR, Schleiss MR. Neuro-pathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin Microbiol Rev. 2009;22(1):99-126.
3. Stratton KR, Durch JS, Lawrence RS. Vaccines for the 21st Century: A Tool for Decision Making: Report of the Committee to Study Priorities for Vaccine Development. Washington, DC, USA: Institute of Medicine; 1999.
4. Schleiss MR. Cytomegalovirus vaccine development. Curr Top Microbiol Immunol. 2008;325:361-382.
5. Pass RF, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009; 360(12):1191-1199.
6. Miller-Kittrell M, Sparer TE. Feeling manipulated: cytomegalovirus immune manipulation. Virol J. 2009;6:4.
7. Sun JC, Lanier LL. The natural selection of herpes-viruses and virus-specific NK cell receptors. Viruses. 2009;1(3):362-382.
8. Yang Z, Bjorkman PJ. Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proc Natl Acad Sci U S A. 2008; 105(29):10095-10100.
9. Occhino M, et al. Dissecting the structural determinants of the interaction between the human cytomegalovirus UL18 protein and the CD85j immune receptor. J Immunol. 2008;180(2):957-968.
10. Wills MR, et al. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J Immunol. 2005; 175(11):7457-7465.
11. Chalupny NJ, Rein-Weston A, Dosch S, Cosman D. Down-regulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem Biophys Res Commun. 2006;346(1):175-181. (Pubitemid 43865981)
12. Stern-Ginossar N, et al. Host immune system gene targeting by a viral miRNA. Science. 2007; 317(5836):376-381.
13. Nachmani D, Lankry D, Wolf DG, Mandelboim O. The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat Immunol. 2010; 11(9):806-813.
14. Ahlfors K, Ivarsson SA, Harris S. Report on a longterm study of maternal and congenital cytomegalovirus infection in Sweden. Review of prospective studies available in the literature. Scand J Infect Dis. 1999;31(5):443-457.
15. Boppana SB, Rivera LB, Fowler KB, Mach M, Britt WJ. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N Engl J Med. 2001;344(18):1366-1371.
16. Yamamoto AY, et al. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am J Obstet Gynecol. 2010; 202(3):297.e1-297.e8.
17. Hansen SG, et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science. 2010;328(5974):102-106.
18. Slavuljica I, et al. Recombinant mouse cytomegalovirus expressing a ligand for the NKG2D receptor is attenuated and has improved vaccine properties. J Clin Invest. 2010;120(12):4532-4545.
19. Krmpotic A, et al. NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med. 2005;201(2):211-220.
20. Lodoen MB, Abenes G, Umamoto S, Houchins JP, Liu F, Lanier LL. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med. 2004;200(8):1075-1081. (Pubitemid 39431131)
21. Pinto AK, Jamieson AM, Raulet DH, Hill AB. The role of NKG2D signaling in inhibition of cytotoxic T-lymphocyte lysis by the murine cytomegalovirus immunoevasin m152/gp40. J Virol. 2007; 81(22):12564-12571.
22. Arapovic J, Lenac Rovis T, Reddy AB, Krmpotic A, Jonjic S. Promiscuity of MCMV immunoevasin of NKG2D: m138/fcr-1 down-modulates RAE-1epsilon in addition to MULT-1 and H60. Mol Immunol. 2009;47(1):114-122.
23. Cicin-Sain L, et al. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J Virol. 2007; 81(24):13825-13834.
24. Crumpler MM, Choi KY, McVoy MA, Schleiss MR. A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/ challenge model of congenital cytomegalovirus infection. Vaccine. 2009;27(31):4209-4218.
25. Söderberg-Nauclér C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006; 259(3):219-246.